Home Cart Sign in  
Chemical Structure| 1632032-53-1 Chemical Structure| 1632032-53-1

Structure of LB-100
CAS No.: 1632032-53-1

Chemical Structure| 1632032-53-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LB-100 is a small-molecular protein phosphatase 2A (PP2A) inhibitor with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LB-100

CAS No. :1632032-53-1
Formula : C13H20N2O4
M.W : 268.31
SMILES Code : OC(C1C(C(N2CCN(C)CC2)=O)[C@]3([H])CC[C@]1(O3)[H])=O
MDL No. :MFCD28167839

Safety of LB-100

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
LB-100, acting as an inhibitor of protein phosphatase 2A (PP2A), shows IC50 values of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells, respectively, indicating its potent inhibitory action[1].[2].[3].

In Vitro:

Cell Line
Concentration Treated Time Description References
OT-1 CD8+ T cells 2 μM 4 hours LB-100 enhances antigen-specific CTL cytotoxicity. PMC5974350
CD4+ T cells 1 μM 5 days LB-100 promotes CD4+ T cell proliferation and Th1 differentiation. PMC5974350
GBMNS (Glioblastoma Neurospheres) 5 µM 24 hours LB100 enhanced G1 cell cycle arrest induced by PRMT5 depletion and increased the anti-GBM effect through necroptotic cell killing. PMC8408848
MiaPaCa-2 cells 1 or 3 μmol/L 2 hours pre- and 24 hours post-IR LB100 treatment resulted in significant radiosensitization, with RERs ranging from 1.2 to 1.4. PMC3754450
Panc-1 cells 1 or 3 μmol/L 2 hours pre- and 24 hours post-IR LB100 treatment resulted in significant radiosensitization, with RERs ranging from 1.2 to 1.4. PMC3754450
U-CH1 0–20 µM 24, 48, 72 hours To evaluate the effect of LB100 on chordoma cell proliferation, results showed that LB100 alone had a limited effect on cell proliferation, but in combination with radiation, it significantly inhibited cell proliferation. PMC5961117
CCL-241 cells 1 or 3 μmol/L LB100 treatment produced little to no radiosensitization in normal cells. PMC3754450
UM-Chor1 0–20 µM 24, 48, 72 hours To evaluate the effect of LB100 on chordoma cell proliferation, results showed that LB100 alone had a limited effect on cell proliferation, but in combination with radiation, it significantly inhibited cell proliferation. PMC5961117
JHC7 0–20 µM 24, 48, 72 hours To evaluate the effect of LB100 on chordoma cell proliferation, results showed that LB100 alone had a limited effect on cell proliferation, but in combination with radiation, it significantly inhibited cell proliferation. PMC5961117
HCC cells 10 μM LB-100 significantly decreased PP2Ac activity in high PDCD10 expressing cells PMC8440642
IOμM-LEE cells 2.5 µM 4 hours LB-100 enhanced the radiosensitivity of meningioma cells and reduced survival fraction in clonogenic assays. PMC5748254
GAR cells 2.5 µM 4 hours LB-100 enhanced the radiosensitivity of meningioma cells and reduced survival fraction in clonogenic assays. PMC5748254
CH-157 cells 2.5 µM 4 hours LB-100 enhanced the radiosensitivity of meningioma cells and reduced survival fraction in clonogenic assays. PMC5748254

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CT26 colon cancer model Intraperitoneal injection 2 mg/kg Once daily for 2 weeks LB-100 combined with aPD-1 significantly inhibits tumor growth and prolongs survival in the CT26 model. PMC5974350
Mice Intracranial GBM mouse model Intraperitoneal injection 10 mg/kg Once daily for 4 days Combination treatment of LB100 with PRMT5 depletion significantly reduced tumor size and prolonged survival in mice, while LB100 treatment alone had no survival benefit. PMC8408848
mice Ube3am−/p+ mice model intraperitoneal injection 0.16 mg/kg Every 2 days for 30 days LB-100 significantly ameliorated the deficits in motor coordination and learning in Ube3am?/p+ mice, and restored the deficits in excitatory synaptic transmission and dendritic spine morphology PMC6589679
nude mice MiaPaCa-2 xenograft model I.P. 1.5 mg/kg Every other day, until the end of the study LB100 alone significantly delayed tumor growth, and when combined with radiation, the time required for tumor volume doubling was significantly extended. PMC3754450
NSG mice Subcutaneous xenograft model Intraperitoneal injection 1 mg/kg every 2 days starting at P14 and continuing until P30 To evaluate the effect of LB100 in combination with radiation on chordoma xenograft growth, results showed that the combination treatment significantly delayed tumor growth. PMC5961117
BALB/c nude mice Orthotopic tumor model Intraperitoneal injection 1.5 mg/kg once a day, 5 days a week for 2 weeks LB-100 significantly inhibited tumor growth and lung metastasis of orthotopic tumors derived from HCC cells with high PDCD10 expression PMC8440642
BALB/c nude mice Intracranial orthotopic meningioma mouse model Intraperitoneal injection 1 mg/kg Twice daily for 3 days The combined treatment of LB-100 and radiation significantly prolonged the survival of mice with xenografts. PMC5748254

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03886662 Myelodysplastic Syndromes PHASE1|PHASE2 RECRUITING 2025-07-21 H. Lee Moffitt Cancer Center &... More >> Research Institute, Tampa, Florida, 33612, United States Less <<
NCT03027388 Astrocytoma, Grades II, III an... More >>d IV|Glioblastoma Multiforme|Giant Cell Glioblastoma|Glioma|Oligodendrogliomas Less << PHASE2 COMPLETED 2022-08-31 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.73mL

0.75mL

0.37mL

18.64mL

3.73mL

1.86mL

37.27mL

7.45mL

3.73mL

References

 

Historical Records

Categories